Earnings ·
Dianthus Therapeutics reports Q3 net loss of $0.81 per share and holds $1.2 billion in cash
DNTHDianthus Therapeutics, Inc.
Dianthus Therapeutics reported a net loss of $46.6 million, or $0.81 per share, for the quarter ended September 30, 2026, compared to a $36.8 million loss in the prior-year period. Research and development expenses rose to $45.6 million from $32.5 million, driven by higher clinical costs and increased headcount supporting Phase 2 and Phase 3 trials of claseprubart. General and administrative expenses totaled $14.1 million against $8.2 million previously. The company ended the quarter with approximately $1.2 billion in cash, cash equivalents, and investments, providing a runway into 2030. Clinical updates include top-line results for the Phase 2 MoMeNtum trial of claseprubart in multifocal motor neuropathy expected in December 2026, and Part A data from the Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy projected by year-end 2027. Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases.